الفهرس 
Acknowledgements
Chronic kidney disease (CKD)Only 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Hyperphosphatemia is a common complication of chronic kidney disease (CKD) haemodialysis (HD) patients, and leads to a variety of complications, such as secondary hyperparathyroidism, mineral bone diseases, calcific uremic arteriolopathy, and cardiovascular calcification Therefore, the management of hyperphosphatemia in patients with CKD will reduce the risk of these complications. Management of hyperphosphatemia in patients with ESRD is not adequate. Therefore, the discovery and development of new drugs as Niacin in this indication is a priority for both medical and health- economic reasons. This RCT study was performed to assess the efficacy of niacin in management of hyperphosphatemia in ESRD patients undergoing hemodialysis (HD). Our study included 50 patients with ESRD and hyperphosphatemia on regular HD; those patients were randomly subdivided into; niacin group included 25 patients received niacin 750 mg daily titrated up to 1500 mg at week 5 and continued till the end of the study in addition to usual calcium based phosphate binders and control group included 25 patients received only usual calcium based phosphate binders . There was a decrease in phosphate values during the first three months of the study in niacin group. Measuring phosphate values in consecutive months showed significant changes in phosphate levels at third month (5.90 ± 0.52 vs. 6.42 ± 0.65 (mEq/l); P< 0.001) and at sixth month (5.12 ± 0.41 vs. 5.76 ± 0.47 (mEq/l); P< 0.001) in the niacin group in comparison to the control group.